Ouro Medicines

Ouro Medicines is a biotechnology company focused on developing immune reset therapeutics aimed at treating chronic immune-mediated diseases. The company operates in the biopharmaceutical sector, targeting patients who suffer from conditions that involve the immune system. Ouro Medicines leverages its scientific expertise and a strong track record in advancing cell-depleting therapies through clinical stages. The business model revolves around research and development, with a significant portion of its funding directed towards creating novel T cell engagers that have the potential to reset the immune system. Ouro Medicines generates revenue through partnerships and collaborations, as well as through the development and commercialization of its therapeutic assets. The company was founded by Monograph Capital in collaboration with GSK and has secured substantial funding from investors such as TPG, NEA, and Norwest. With a promising clinical stage asset and a robust discovery pipeline, Ouro Medicines is positioned to redefine treatment paradigms for immune-mediated diseases.

Keywords: biotechnology, immune reset, therapeutics, chronic diseases, T cell engagers, clinical pipeline, biopharmaceutical, research, development, partnerships